Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008

BACKGROUND: Drug resistance of B-cell precursor acute lymphoblastic leukemia (BP-ALL) cells is conferred by both intrinsic and extrinsic factors, which could be targeted to promote chemo-sensitization. Our previous studies showed that Galectin-3, a lectin that clusters galactose-modified glycoprotei...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Paz, Helicia, Joo, Eun Ji, Chou, Chih-Hsing, Fei, Fei, Mayo, Kevin H., Abdel-Azim, Hisham, Ghazarian, Haike, Groffen, John, Heisterkamp, Nora
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5870532/
https://ncbi.nlm.nih.gov/pubmed/29580262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0721-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars